The treatment of bleeding episodes in patients with<unk> 's thrombasthenia includes local measures with or without anti-fibrinolytic therapy first, followed by platelet transfusion, and rFVIIa if bleeding persists. However, the majority of cases of<unk> 's thrombasthenia bleeds are self-limited and only require supportive care. Other options include desmopressin (DDAVP) which increases tissue plasminogen activator (tPA), FVIII, and von Willebrand factor (VWF) in plasma. However, it has no significant effect on platelet disorders. rFVIIa manages bleeding in most patients with<unk> 's thrombasthenia.
Glanzmann's thrombasthenia medical therapy
Von Willebrand disease medical therapy
Essential thrombocytosis medical therapy
Heparin-induced thrombocytopenia medical therapy
Disseminated intravascular coagulation medical therapy
Glanzmann's thrombasthenia future or investigational therapies
Heparin-induced thrombocytopenia future or investigational therapies
Thrombotic thrombocytopenic purpura medical therapy